Sex After Menopause: What Changes and What Helps

Sexual comfort can change after menopause, but pain should not be treated as inevitable. Describe the location, timing, and duration of symptoms, along with bleeding, discharge, skin changes, and urinary concerns. Those details help distinguish GSM from other conditions.

The changes have a name: genitourinary syndrome of menopause

GSM is a possible diagnosis when genital, sexual, or urinary symptoms develop with lower estrogen after menopause. It may involve one symptom or several.

The term covers vaginal dryness, burning, irritation, pain with penetration, and some urinary symptoms ¹. Estimates range from about 27% to 84% of postmenopausal women, partly because studies use different definitions ¹.

Urinary urgency, painful urination, and recurrent urinary tract infections can occur with GSM. They can also have other causes. New symptoms need an appropriate urine, pelvic, or skin evaluation rather than automatic attribution to menopause.

How does vaginal estrogen help the bladder?

Local estrogen has its strongest evidence for vaginal dryness and pain. Evidence is moderate for urge incontinence and recurrent urinary tract infections. It is weaker for painful urination, frequency, urgency, and nighttime urination ¹. Tell the clinician about urinary symptoms so they can be assessed rather than assumed to be GSM.

Is this what used to be called vaginal atrophy?

Yes. In 2014, sexual-health and menopause societies adopted GSM as a broader replacement for “vulvovaginal atrophy” ². The newer term includes urinary and sexual symptoms as well as vaginal tissue changes.

A diagnosis should follow the history and examination, especially when there is bleeding, discharge, a visible skin change, or severe pain.

What helps, from lubricants to prescription options

For mild symptoms, first-line options include a lubricant during sexual activity and a vaginal moisturizer used regularly ¹. A lubricant reduces friction for a specific encounter. A moisturizer is intended to improve day-to-day comfort.

Low-dose vaginal estrogen can improve dryness and pain when nonprescription options are not enough ¹. A Cochrane review included 30 trials and 6,235 women. In its placebo-controlled comparisons, more women reported improvement with rings, tablets, or creams than with placebo. Evidence quality was low to moderate because of reporting limitations and imprecision ³.

Other prescription options include vaginal DHEA (prasterone) and oral ospemifene for moderate-to-severe symptoms ¹. DHEA is applied locally. Ospemifene is a systemic oral selective estrogen-receptor modulator, so its contraindications and boxed-warning information differ from local vaginal products.

Our sexual-wellness treatment comparison places these options beside treatments for desire and erectile function. Product choice depends on symptom severity, medical history, cost, preference, and whether urinary symptoms are present.

Why this one doesn't fade the way hot flashes do

GSM differs from hot flashes because it generally persists and may worsen without effective treatment ¹. That makes continuing symptoms worth discussing instead of waiting for them to resolve on their own.

GSM can affect sexual function, urinary health, and quality of life ¹. Earlier evaluation can reduce prolonged discomfort and identify another cause if the symptoms do not fit GSM. Pain during sex is a medical concern at any age.

Desire is a separate question

Sexual desire may be spontaneous, responsive to intimacy or arousal, or a mixture of both. A responsive-desire model was developed to describe common experiences that do not begin with spontaneous interest ⁴. It should not be treated as the only normal pattern for every woman.

Low desire can reflect pain, sleep, mood, medications, health, relationship context, and hormonal changes. Local estrogen is not a direct desire treatment. It may improve sexual experience by reducing GSM-related dryness and pain, which can remove one reason for avoiding sex.

Libido may improve when pain, sleep disruption, or another contributor is treated, but a response cannot be guaranteed. Some desire-directed prescription drugs are approved only for selected premenopausal women. Our sexual-wellness treatment guide explains those limits. The sexual-health overview and low-libido guide cover the broader assessment.

Is vaginal estrogen safe, and who to talk to

Low-dose vaginal estrogen has minimal systemic absorption, but minimal does not mean zero ¹. Systemic estrogen and local vaginal estrogen therefore require different risk discussions. A progestogen is generally not recommended with low-dose vaginal estrogen, although people at increased endometrial-cancer risk may need individualized surveillance ¹.

The Women's Health Initiative Observational Study followed 45,663 women with an intact uterus for a median of 7.2 years ⁵. Rates of stroke, breast cancer, endometrial cancer, and blood clots did not differ significantly between vaginal-estrogen users and nonusers. This was observational evidence, not a randomized safety trial. Randomized endometrial-safety data beyond one year are unavailable ¹.

Systemic hormone therapy has a separate benefit-risk profile, covered in the menopause hormone therapy guide. When symptoms are limited to GSM and nonprescription options are insufficient, guidance recommends low-dose local vaginal therapy rather than systemic treatment ⁶. A history of breast cancer, unexplained bleeding, or another complex condition requires individualized discussion.

• Describe each symptom

  Mention dryness, burning, pain, bleeding, discharge, skin changes, and urinary symptoms.
• Ask whether GSM fits

  Request an evaluation for GSM and other possible causes instead of assuming the diagnosis.
• Choose a starting option

  Discuss whether lubricants or moisturizers are enough and when a prescription treatment makes sense.
• Review your safety context

  Ask how a local product differs from systemic therapy given your cancer, bleeding, clot, and medication history.

Follow-up should assess symptom relief, side effects, bleeding, and whether the diagnosis still fits.